Investors are often prone to look into stocks which may have clocked notable gains over a sustained period of time before considering looking into it. Gains made over a period of one week is often seen as a good barometer and by that token, it may be the right time to perhaps start tracking the Therma Bright Inc (OTCMKTS:TBRIF) (TSXV: THRM) stock.

In the past week, the stock has managed to garner a fair degree of attention from investors and managed to generate gains of as much as 10% as a consequence. There has been no news about the company this week so far but it might be the right time to look into a key announcement from the company back on January 31, 2022.

Update on U.S. Clinical Performance Study

The company is currently best known for having developed the AcuVid™ COVID-19 Rapid Antigen Saliva Test and yesterday the company announced that it had completed the subject recruitment initiative as directed by the United States Clinical Performance Study. It was a significant development for the company and one that could eventually go a long way towards the potential approval of the product.

As soon as the company is able to tabulate the final clinical data, it is going to submit an Emergency Use Authorization consideration filing with the United States Food and Drug Administration. Rob Fia, who is the Chief Executive Officer of the company, thanked the continued patience of the company’s partners, shareholders, and clients as it continued to work on the project.

Completes U.S. Clinical Performance Study Subject Recruitment

The news is clearly a positive for the company and the reaction of the investors is a testament to the fact that they believe that the product is possibly on the right track in terms of development. While the rally in the Therma Bright stock is likely to bring it into focus among investors in a big way over the course of the coming days, it may still be the right idea for investors to keep an eye on the developments closely. Any tiny bit of news with regards to the company could have an impact on the stock price.